hapabapa/iStock Editorial by way of Getty Photographs Novo Nordisk (NVO) stated it has raised its 2023 gross sales development steerage, due largely to higher-than-expected gross sales for its GLP-1 medicine. The Danish drugmaker stated it now sees 2023 gross sales rising by 32% to 38% over final 12 months, up from its August steerage of …
hapabapa/iStock Editorial by way of Getty Photographs
Novo Nordisk (NVO) stated it has raised its 2023 gross sales development steerage, due largely to higher-than-expected gross sales for its GLP-1 medicine.
The Danish drugmaker stated it now sees 2023 gross sales rising by 32% to 38% over final 12 months, up from its August steerage of 27% to 33%. Working development is now seen as rising 40% to 46%, up from its prior estimate of 31% to 37%. Estimates are primarily based on fixed trade charges.
Novo stated the up to date steerage displays larger full-year expectations for Ozempic volumes bought within the US and gross-to-net gross sales changes for Ozempic and Wegovy within the US.
Ozempic and Wegovy are model names for the GLP-1 drug semaglutide, which is accredited within the US for the remedy of diabetes and weight reduction.
Novo stated that firm gross sales grew by 38% for Q3 and 33% for the primary 9 months of 2023. Working revenue development elevated by 47% in Q3 and 37% for the primary 9 months of the 12 months.
The corporate is predicted to launch its nine-month monetary report on Nov. 2.
Keep in touch with our news & offers
